Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07083765 · ClinicalTrials.gov registry record · Phase 3
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
A Phase 3 study of Hypertension and Hypertension,Essential, sponsored by Ablative Solutions.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 142
- Enrollment target
- 1
- Study location
NCT07083765 is a Phase 3 study of Hypertension and Hypertension,Essential that is actively recruiting participants, run by Ablative Solutions. The registered enrollment target is 142 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07083765, a Phase 3 study of Hypertension and Hypertension,Essential, is actively recruiting participants, sponsored by Ablative Solutions.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 142 participants
- Enrollment target
- 1
- Study location
Study Summary
To obtain an assessment of the efficacy and safety of renal denervation by dehydrated alcohol injection, USP administered via the Peregrine System™ Infusion Catheter in hypertensive subjects in the absence of antihypertensive medications.
Conditions Studied
Interventions
- DRUG Dehydrated Alcohol Injection, USP
- PROCEDURE Sham procedure
Study Locations (1)
Tennessee
- Tennova Turkey Creek Medical Center - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2025-09-01 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07083765
The ClinicalTrials.gov registry entry for NCT07083765 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (96% lower). The listed sponsor is Ablative Solutions, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Dehydrated Alcohol Injection, USP is the first listed.
NCT07083765 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT07083765 about?
NCT07083765 is a clinical study titled "Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)". To obtain an assessment of the efficacy and safety of renal denervation by dehydrated alcohol injection, USP administered via the Peregrine System™ Infusion Catheter in hypertensive subjects in the absence of antihypertensive medications.
What is the current status of trial NCT07083765?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 142 participants. The study started on 2025-09-01. Estimated completion is 2027-10-31.
What conditions does trial NCT07083765 study?
This clinical trial studies the following conditions: Hypertension, Hypertension,Essential.
What interventions are being tested in trial NCT07083765?
The interventions under investigation include: Dehydrated Alcohol Injection, USP (DRUG), Sham procedure (PROCEDURE).
Who is sponsoring clinical trial NCT07083765?
This trial is sponsored by Ablative Solutions, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07083765 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
-
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.